Here’s the skinny on the CRISPR patent saga between the Broad Institute and the CVC group

Here’s the skinny on the CRISPR patent saga between the Broad Institute and the CVC group

CRISPR was first reported by Jennifer Doudna and Emmanuelle Charpentier in 2012, as an outgrowth of their work on bacterial ...
ADVERTISEMENT
‘Exceptionally potent yet easily scalable’: Synthetic biology-based COVID vaccine could pull ahead of current frontrunners

‘Exceptionally potent yet easily scalable’: Synthetic biology-based COVID vaccine could pull ahead of current frontrunners

Years ago, researchers learned that, when made with biotechnology, some viral proteins could spontaneously assemble themselves into “virus-like particles,” or ...
In a politically divided America, here's how the biotechnology sector sees its future

In a politically divided America, here’s how the biotechnology sector sees its future

[W]hat does Joe Biden’s presidency mean for biopharma? Part of that question will rest on whether Democrats can pull of ...
china

Chinese biopharma firms ‘well ahead’ in race to use CRISPR in humans

Contrary to what you might believe, biopharma companies in the US are not the leaders in clinical trials using gene ...
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.